Score Overview
Explore the 2021 public Archive ranking →
Where Jazz Pharmaceuticals PLC has ranked, year by year
Showing 5 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- JAZZ
2013: 4.4% · 2021: 32.9% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-30 | $ 231.52 | — |
1 Year2025-09-30 | $ 131.80 | 75.66% |
5 Years2021-09-30 | $ 130.21 | 77.81% |
10 Years2016-09-30 | $ 121.48 | 90.58% |
All Time2007-06-01 | $ 17.73 | 13x |
| Period | Last Price2026-09-30 | 1 Year2025-09-30 | 5 Years2021-09-30 | 10 Years2016-09-30 | All Time2007-06-01 |
|---|---|---|---|---|---|
| Price | $ 231.52 | $ 131.80 | $ 130.21 | $ 121.48 | $ 17.73 |
| Return | — | 75.66% | 77.81% | 90.58% | 13x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 4.60B | $ 940M | $ 2.19B |
| 2025 | $ 4.26B | -$ 356M | $ 2.44B |
| 2024 | $ 4.06B | $ 560M | $ 2.99B |
| 2023 | $ 3.83B | $ 414M | $ 1.62B |
| 2022 | $ 3.65B | -$ 224M | $ 881M |
| 2021 | $ 3.09B | -$ 328M | $ 591M |
| 2020 | $ 2.36B | $ 238M | $ 2.13B |
| 2019 | $ 2.16B | $ 523M | $ 1.07B |
| 2018 | $ 1.89B | $ 447M | $ 824M |
| 2017 | $ 1.61B | $ 487M | $ 601M |
| 2016 | $ 1.48B | $ 396M | $ 425M |
| 2015 | $ 1.32B | $ 329M | $ 988M |
| 2014 | $ 1.17B | $ 58M | $ 684M |
| 2013 | $ 872M | $ 216M | $ 636M |
| 2012 | $ 585M | $ 288M | $ 387M |
| 2011 | $ 272M | $ 124M | $ 157M |
| 2010 | $ 173M | $ 32M | $ 44M |
| 2009 | $ 128M | -$ 6M | $ 15M |
| 2008 | $ 67M | -$ 184M | $ 25M |
| IPO2007 | $ 65M | -$ 138M | $ 102M |
Jazz Pharmaceuticals PLC fundamental performance
Between 2020 and 2025, revenue grew from $ 2.36B to $ 4.26B and net income went from $ 238M to -$ 356M. Revenue increased in every one of those 5 years; net income in 4.
Across Jazz Pharmaceuticals PLC's full reported history, from 2007 to 2025, revenue grew from $ 65M to $ 4.26B and net income went from -$ 138M to -$ 356M. Revenue increased in 100% of the years measured; net income in 63%.
Jazz Pharmaceuticals PLC currently holds a 5-year HDB Score of 8.4 out of 10. How the HDB Score is calculated.
Membership
Continue JAZZ’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
